CVS Health: Navigating Near-Term Turbulence

Current sell-side consensus anticipates non-GAAP earnings of $0.99 per share for the fourth quarter, a moderate decrease from the $1.19 reported in Q4 2024. While an earnings beat remains a possibility, investor attention may be disproportionately focused on the forward-looking guidance. Specifically, the impact of revised Medicare Advantage rates—recently proposed at a 0.9% increase—will likely be scrutinized. UnitedHealth (UNH +2.89%), having already released an underwhelming outlook following the announcement of these rates, provides a cautionary precedent.







